Pre-made Zimbirelimab benchmark antibody (Whole mAb, anti-PDCD1/PD-1 therapeutic antibody, Anti-CD279/PD1/SLEB2/hSLE1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-1058

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-INN-1058 Category Tag

Product Details

Anti-PDCD1/PD-1 therapeutic antibody (Pre-made Zimbirelimab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Zimbirelimab Biosimilar, Whole Mab, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody

INN Name

zimbirelimab

Target

PDCD1

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG4 – lambda

VD LC

IgG4 – lambda

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Arcus?Biosciences, Inc. (Hayward CA USA)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

OmniRat (Open Monoclonal Technology Inc (OMT))

Previous Name

NA

Gm Offical Target Name

PDCD1

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide